RAVEN HOUSTON: Open Payments
NPI 1235753351 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$973 in 25 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $746 · 2025 $973
Food & beverage: $886Education: $87
| Company | Payments | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. | 5 | $217 |
| Adaptive Biotechnologies Corporation | 2 | $168 |
| SOBI, INC | 5 | $163 |
| Lilly USA, LLC | 2 | $113 |
| AstraZeneca Pharmaceuticals LP | 3 | $100 |
| GlaxoSmithKline, LLC. | 3 | $76 |
| Celgene Corporation | 1 | $31 |
| PharmaEssentia USA Corporation | 1 | $30 |
| Incyte Corporation | 1 | $29 |
| Astellas Pharma US Inc | 1 | $27 |
Products named: clonoSEQ, Vonjo, REVUFORJ, CALQUENCE, OJJAARA, Gamifant, REBLOZYL, BESREMI.
Industry payments across TX — which companies pay providers there.
